Study in Immunity highlights Asgard's ability to generate potent immunogenic tertiary lymphoid structures (imgTLSs) solely by reprogramming tumor ...

Researchers conducted a comprehensive in silico study to evaluate the immunogenic potential of Heat Shock Protein 90 (Hsp90) ...

Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune-based therapies). Despite harboring the highest tumor mutational burden of ...

A 2025 review in Discover Immunity explores how bacterial extracellular vesicles can serve as self-adjuvanted vaccine platforms, highlighting their immunomodulatory potential and the challenges in ...

A new study reveals that microbiota and their metabolites can effectively reprogram immunogenic cell death (ICD), a unique form of cell death that activates the body‘s immune system against tumors.

MIT researchers tuned antigen display on M13 particles to improve tumor protection in mice, advancing a potential platform ...

Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ ...

Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...

Newswise — Traditional cancer treatments like chemotherapy and radiotherapy can induce immunogenic cell death (ICD), but their efficacy is often limited by drug resistance, severe off-target toxicity, ...